Kalpit Patel
Stock Analyst at B. Riley Securities
(0.91)
# 3,786
Out of 4,918 analysts
59
Total ratings
34.88%
Success rate
-12.34%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kalpit Patel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DERM Journey Medical | Maintains: Buy | $9 → $12 | $6.99 | +71.67% | 6 | Jul 30, 2025 | |
| KYMR Kymera Therapeutics | Upgrades: Buy | $38 → $60 | $42.96 | +39.66% | 5 | Jun 3, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Neutral | $17 → $14 | $8.11 | +72.63% | 7 | May 2, 2025 | |
| AVBP ArriVent BioPharma | Initiates: Buy | $37 | $18.67 | +98.23% | 1 | Mar 20, 2025 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $20 → $24 | $21.91 | +9.54% | 6 | Mar 5, 2025 | |
| GERN Geron | Maintains: Buy | $5.5 → $3.5 | $1.17 | +199.15% | 4 | Feb 18, 2025 | |
| VSTM Verastem | Maintains: Buy | $7 → $9 | $6.08 | +48.03% | 4 | Jan 31, 2025 | |
| FHTX Foghorn Therapeutics | Initiates: Buy | $10 | $5.00 | +100.00% | 1 | Jan 30, 2025 | |
| PDSB PDS Biotechnology | Maintains: Buy | $9 → $7 | $1.09 | +542.20% | 5 | Nov 25, 2024 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $85 → $40 | $9.31 | +329.65% | 2 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $3 | $0.50 | +500.00% | 2 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $20 | $17.41 | +14.88% | 3 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $30 | $1.60 | +1,775.00% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $34 → $36 | $9.98 | +260.72% | 2 | Jul 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $90 | $2.11 | +4,165.40% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $18 | $1.08 | +1,566.67% | 2 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $5 | $1.95 | +156.41% | 2 | Jul 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $14.72 | +579.35% | 1 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 | $9.65 | +677.20% | 2 | Sep 3, 2021 |
Journey Medical
Jul 30, 2025
Maintains: Buy
Price Target: $9 → $12
Current: $6.99
Upside: +71.67%
Kymera Therapeutics
Jun 3, 2025
Upgrades: Buy
Price Target: $38 → $60
Current: $42.96
Upside: +39.66%
Bicycle Therapeutics
May 2, 2025
Maintains: Neutral
Price Target: $17 → $14
Current: $8.11
Upside: +72.63%
ArriVent BioPharma
Mar 20, 2025
Initiates: Buy
Price Target: $37
Current: $18.67
Upside: +98.23%
Rigel Pharmaceuticals
Mar 5, 2025
Maintains: Neutral
Price Target: $20 → $24
Current: $21.91
Upside: +9.54%
Geron
Feb 18, 2025
Maintains: Buy
Price Target: $5.5 → $3.5
Current: $1.17
Upside: +199.15%
Verastem
Jan 31, 2025
Maintains: Buy
Price Target: $7 → $9
Current: $6.08
Upside: +48.03%
Foghorn Therapeutics
Jan 30, 2025
Initiates: Buy
Price Target: $10
Current: $5.00
Upside: +100.00%
PDS Biotechnology
Nov 25, 2024
Maintains: Buy
Price Target: $9 → $7
Current: $1.09
Upside: +542.20%
Corbus Pharmaceuticals Holdings
Sep 20, 2024
Maintains: Buy
Price Target: $85 → $40
Current: $9.31
Upside: +329.65%
Jun 18, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.50
Upside: +500.00%
May 9, 2024
Downgrades: Neutral
Price Target: $25 → $20
Current: $17.41
Upside: +14.88%
Dec 12, 2023
Downgrades: Neutral
Price Target: $90 → $30
Current: $1.60
Upside: +1,775.00%
Jul 25, 2023
Maintains: Buy
Price Target: $34 → $36
Current: $9.98
Upside: +260.72%
Nov 11, 2022
Downgrades: Neutral
Price Target: $270 → $90
Current: $2.11
Upside: +4,165.40%
Sep 22, 2022
Maintains: Buy
Price Target: $21 → $18
Current: $1.08
Upside: +1,566.67%
Jul 19, 2022
Maintains: Buy
Price Target: $6 → $5
Current: $1.95
Upside: +156.41%
Jan 24, 2022
Maintains: Buy
Price Target: $240 → $100
Current: $14.72
Upside: +579.35%
Sep 3, 2021
Downgrades: Neutral
Price Target: $75
Current: $9.65
Upside: +677.20%